{"commentary":{"count":89,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":38,"x_thread":29,"podcast":21,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03815890\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"BELLINI","nct_id":"NCT03815890","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bellini-nct03815890. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"BELLINI","arms":[{"description":"Nivolumab","label":"1A; LumB","type":"EXPERIMENTAL"},{"description":"Nivolumab","label":"1B; TNBC","type":"EXPERIMENTAL"},{"description":"Nivolumab and ipilimumab","label":"2A; LUMB","type":"EXPERIMENTAL"},{"description":"Nivolumab and ipilimumab","label":"2B; TNBC","type":"EXPERIMENTAL"},{"description":"Nivolumab and ipilimumab","label":"3B; TNBC, High TIL","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2033-01-01","type":"ESTIMATED"},"conditions":["Breast Cancer"],"enrollment":{"count":80,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Nivolumab","type":"DRUG"},{"name":"Ipilimumab","type":"DRUG"},{"name":"Ipilimumab","type":"DRUG"}],"last_update":"2024-05-30","lead_sponsor":"The Netherlands Cancer Institute","official_title":"Pre-operative Phase II Trial for Breast Cancer With Nivolumab in Combination With Novel IO (BELLINI Trial)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2031-01-01","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Pathological complete response rate per cohort,","timeFrame":"up to 3 weeks after surgery, an average of 6 months"}],"references":[{"citation":"Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024 Nov;30(11):3223-3235. doi: 10.1038/s41591-024-03249-3. Epub 2024 Sep 16.","pmid":"39284953","type":"DERIVED"}],"start_date":{"date":"2019-10-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO","url":"https://clinicaltrials.gov/study/NCT03815890"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bellini-nct03815890"}